Skip to content

Arrowhead Research ARWR Net Investment in Lease

Net Investment in Lease at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
ALN
Alnylam PharmaceuticalsALNY
BridgeBio Pharma logo
BridgeBio PharmaBBIO
Madrigal Pharmaceuticals, Inc. logo
Madrigal Pharmaceuticals, Inc.MDGL
Revvity logo
RevvityRVTY
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX

Other financials

Income statement

See full
Revenue$73.7M-86.4%
Operating income-$141.3M-137%
Net income-$132.7M-136%
EPS (diluted)-$0.93-134%

Balance sheet

See full
Cash & equivalents$188.5M+1.5%
Total debt$107.9M-5.6%
Total equity$614.0M-10.1%
Total assets$2.3B+44.2%

Cash flow

See full
Operating cash flow$84.4M-81.6%
CapEx$2.6M-51.6%
Free cash flow$81.9M-82.0%

Valuation

See full
Market cap$11.52B+402%
Enterprise value$11.44B+418%
P/S18.5×+14.3×

Profitability

See full
Operating margin-35.7%+63.6pp
Net margin-48.4%+240pp
FCF margin1.8%+0.9pp

Returns & leverage

See full
Return on equity-46.4%+341pp
Debt / equity0.2×0.0×
Current ratio6.2×+1.1×

Where this comes from

Reported directly by Arrowhead Research in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.

The official record: Arrowhead Research’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arrowhead Research's net investment in lease.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Arrowhead Research's net investment in lease?
Arrowhead Research (ARWR) reported net investment in lease of $42.79M in Q1 2026.
How has Arrowhead Research's net investment in lease changed year-over-year?
Arrowhead Research's net investment in lease decreased by 3.7% year-over-year, from $44.45M to $42.79M.
What is the long-term trend for Arrowhead Research's net investment in lease?
Over 5 years (2020 to 2025), Arrowhead Research's net investment in lease has grown at a 22.2% compound annual growth rate (CAGR), from $16.14M to $43.89M.